Immuneering Corporation
IMRX
$1.45
-$0.01-0.69%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -15.76% | 3.74% | 5.18% | -7.74% | 6.77% |
| Depreciation & Amortization | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 13.84% | 9.68% | 10.43% | 4.40% | 16.56% |
| Operating Income | -13.84% | -9.68% | -10.43% | -4.40% | -16.57% |
| Income Before Tax | -19.68% | -15.90% | -15.52% | -5.17% | -13.88% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -19.68% | -15.90% | -15.52% | -5.17% | -13.88% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -19.68% | -15.90% | -15.52% | -5.17% | -13.88% |
| EBIT | -13.84% | -9.68% | -10.43% | -4.40% | -16.57% |
| EBITDA | -13.95% | -9.66% | -10.41% | -4.33% | -16.58% |
| EPS Basic | -12.83% | -13.66% | -11.59% | 5.31% | -2.73% |
| Normalized Basic EPS | -12.79% | -10.50% | -11.62% | 5.55% | -1.42% |
| EPS Diluted | -12.83% | -13.66% | -11.59% | 5.31% | -2.73% |
| Normalized Diluted EPS | -12.79% | -10.50% | -11.62% | 5.55% | -1.42% |
| Average Basic Shares Outstanding | 6.08% | 1.97% | 3.51% | 11.07% | 10.84% |
| Average Diluted Shares Outstanding | 6.08% | 1.97% | 3.51% | 11.07% | 10.84% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |